ArticleJournal of virology2011
Capturing the natural diversity of the human antibody response against vaccinia virus.
Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies.Frontiers in immunology · 2026Review
- Convergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Machine learning-supported framework for the classification of mpox infection and MVA immunization from multiplexed serology data.Nature communications · 2025Article
- Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase.Journal of virology · 2025Article
- Monoclonal Antibodies in Light of Mpox Outbreak: Current Research, Therapeutic Targets, and Animal Models.Antibodies (Basel, Switzerland) · 2025Review
- Pox-AbDab: the orthopoxvirus antibody database.Frontiers in immunology · 2025Article
- Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection.Nature communications · 2024Article
- Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization.Microbiology spectrum · 2023Article
- Development of a novel serological assay for the detection of mpox infection in vaccinated populations.Journal of medical virology · 2023Article
- Monkeypox and the perinatal period: what does maternal-fetal medicine need to know?World journal of pediatrics : WJP · 2023Review
- Article
- A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.Antiviral research · 2021Article
- Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein.Nature communications · 2016Article
- Article
- Clonal redemption of autoantibodies by somatic hypermutation away from self-reactivity during human immunization.The Journal of experimental medicine · 2016Article
- Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease.Current opinion in immunology · 2016Review
- Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8.Vaccine · 2015Review
- Identification of nucleotide-level changes impacting gene content and genome evolution in orthopoxviruses.Journal of virology · 2014Article
- Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.Immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
The eradication of smallpox (variola) and the subsequent cessation of routine vaccination have left modern society vulnerable to bioterrorism employing this devastating contagious disease. The existing, licensed vaccines based on live vaccinia virus (VACV) are contraindicated for a substantial number of people, and prophylactic vaccination of large populations is not reasonable when there is little risk of exposure. Consequently, there is an emerging need to develop efficient and safe therapeutics to be used shortly before or after exposure, either alone or in combination with vaccination. We have characterized the human antibody response to smallpox vaccine (VACV Lister) in immunized volunteers and isolated a large number of VACV-specific antibodies that recognize a variety of different VACV antigens. Using this broad antibody panel, we have generated a fully human, recombinant analogue to plasma-derived vaccinia immunoglobulin (VIG), which mirrors the diversity and specificity of the human antibody immune response and offers the advantage of unlimited supply and reproducible specificity and activity. The recombinant VIG was found to display a high specific binding activity toward VACV antigens, potent in vitro VACV neutralizing activity, and a highly protective efficacy against VACV challenge in the mouse tail lesion model when given either prophylactically or therapeutically. Altogether, the results suggest that this compound has the potential to be used as an effective postexposure prophylaxis or treatment of disease caused by orthopoxviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.